Are Hamsters a Suitable Model for Evaluating the Immunogenicity of RBD-Based Anti-COVID-19 Subunit Vaccines?

Viruses

Arseniya A. Shelemba¹  Olesya E. Viktorina²  Svetlana V. Belenkaya³  Anna V. Zaykovskaya³  Iuliia A. Merkuleva³  Tatiana I. Esina³  Anastasiya A. Isaeva³  Oleg V. Pyankov³  Dmitry N. Shcherbakov³  Vazirbek S. Aripov³  Andrey P. Rudometov³  Alexandr A. Sergeev³  Ekaterina A. Volosnikova³  Elena I. Kazachinskaia³  Valentina S. Nesmeyanova³  Natalia V. Volkova³  Evgeniia A. Kolosova³  Kseniia A. Titova³  Mariya B. Borgoyakova³  Daniil V. Shanshin³  Yulia V. Konyakhina³  Larisa I. Karpenko³  Alexander A. Ilyichev³ 

[1] Federal Research Center of Fundamental and Translational Medicine, 630060 Novosibirsk, Russia;Russian-American Anti-Cancer Center, Altai State University, 656049 Barnaul, Russia;State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia;

关键词: SARS-CoV-2;    COVID-19;    receptor-binding domain;    animal models;   

DOI  :  10.3390/v14051060

来源: DOAJ

【 摘 要 】

Currently, SARS-CoV-2 spike receptor-binding-domain (RBD)-based vaccines are considered one of the most effective weapons against COVID-19. During the first step of assessing vaccine immunogenicity, a mouse model is often used. In this paper, we tested the use of five experimental animals (mice, hamsters, rabbits, ferrets, and chickens) for RBD immunogenicity assessments. The humoral immune response was evaluated by ELISA and virus-neutralization assays. The data obtained show hamsters to be the least suitable candidates for RBD immunogenicity testing and, hence, assessing the protective efficacy of RBD-based vaccines.

【 授权许可】

Unknown